Biocon Biologics CEO On Interchangeability Dynamics For Humira Biosimilar

Biocon Biologics’ CEO indicates that interchangeability may not be pivotal to commercial success in the US for biosimilar adalimumab and that the firm’s Humira rival “checks the key boxes.”